Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines

Lapatinib is an orally administered, dual ErbB1/ErbB2 tyrosine kinase inhibitor (TKI). It is effective in ErbB2 + ve breast cancer treatment. However, lapatinib is associated with diarrhoea with an incidence of 47–75%. The mechanism of ErbB1 TKI-induced diarrhoea remains unclear. ErbB1 or epidermal...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan Mohamad Zain, Wan Nor I′zzah, Bowen, Joanne, Bateman, Emma, Keefe, Dorothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167933/
https://www.ncbi.nlm.nih.gov/pubmed/31905843
http://dx.doi.org/10.3390/biomedicines8010002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167933/
https://www.ncbi.nlm.nih.gov/pubmed/31905843
http://dx.doi.org/10.3390/biomedicines8010002

Ejemplares similares